Australia's most trusted source of pharma news
Tuesday, 26 May 2015
Lost Your Access?
TGA hunting suspect generics
Following the EMA's suspension of 700 generic drugs associated with GVK Biosciences, the TGA is trying to establish if there are any in Australia.
PBS numbers start to slip
With only two months of official figures remaining to be reported for 2014-15, PBS spending is $625 million behind where it was at this time last year.
Exclusive licences not so exclusive
Drafting exclusive licences after the recent Federal Court decision in the
case could prove tricky, says a specialist patent lawyer.
Govt grants GSK $1 million
A GSK advanced manufacturing project at its Boronia sterile liquid pharmaceutical site has received a $1m Federal government grant.
TGA clears Tysabri of cancer risk
After more than a year, the TGA has found "insufficient evidence" of a definite link between Biogen's
and skin cancer.
Arrow returns to shake generics
Head of the 'new' Arrow Pharmaceuticals, Dennis Bastas, talks about his confidence for the business and its place in the Australian generics market.
Tax office takes aim at big pharma
The ATO will be participating in a proposed "multilateral project" looking into the pharmaceutical industry, the Tax Commissioner has said.
Aspen says Aust business safe
Correction to earlier report
: Aspen says it has sold only a part of its portfolio to Strides Arcolab and its Australian business will remain in place.
Janssen to file 10 blockbusters
J&J's Janssen arm plans to file more than 10 new products over the next four years, each with the potential to exceed US$1 billion in revenue it says.
ACCC faces 'difficult' Pfizer appeal
The strong finding on facts in Pfizer's original victory over the ACCC will make the competition watchdog's forthcoming appeal 'difficult' says a senior lawyer.
Pfizer accused of massive tax rort
Fairfax media is alleging that Pfizer has engaged in 'a rapacious tax avoidance scheme' and has reporting 'fake profit figures' to the ASIC.
Price concerns bring another delisting
"No longer viable at the current PBS price" says Leo Pharma as it plans to move psoriasis cream
from the PBS to private script on June 1.
PBAC verdict on asthma meds
The PBAC has rejected a PBS post-market review of asthma drugs in all ages despite a suggestion in the final report of the children's asthma inquiry.
PBS talks: GMiA positive, MA fearful
The GMiA continues to have 'positive dialogue' with the government but MA is fearful that $3bn in forced, ad hoc PBS cuts will threaten medicines access.
New PBAC chair knows sector: MA
MA has welcomed Professor Andrew Wilson as the new PBAC chair and looks forward to knowing more about proposed reform of its operations.
Sanofi seeks govt cash to train GPs
Sanofi is seeking funding support from the government for its Insulin Leadership Summit GP education program.
Competition grows for $38m Alimta
Competition for Eli Lilly's $38m cancer drug
is growing with four generic companies having registered rival brands on the ARTG although Lilly still has the sole PBS listing.
What will a 'sustainable' PBS look like?
Health Minister Sussan Ley says she must fashion a 'sustainable' PBS if new medicines are to be listed in future. Her choices are many experts say but few will please pharma.
PBS Top Five
Infectious diseases - a market in suspension
The infectious diseases market is expected to surge once new hep C treatments such as
are PBS listed but right now it looks like prescribers are holding back.
Fast track for pancreatic cancer treatment
The FDA fast tracks filings for pancreatic cancer, multiple myeloma plus new filings on horizon for asthma and eye disease.
Overseas posts not just for managers
You don't have to be at managerial level to gain an overseas posting from some of Australia's top pharma companies. How's it done?
Events & Conferences
© 2003 - 2015 Lush Media
Pharma in Focus
Jolly Good Design